new glp 1 drugs in development What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 AGONISTS AVAILABLE AND IN

However, to date, extensive RCTs have shown no correlation between specific GLP-1 RAs and increased cancer risk

Thats happening right now

After treatment for 12 months, MDS-UPDRS Part III scores improved slightly by 0.04 points in the lixisenatide group and decreased by 3.04 points in the placebo group

Bettcher BM, Tansey MG, Dorothe G, et al

[5] Each formulation has distinct dosing schedules, with some administered daily and others weekly

LegitScript tackles the sale of problematic healthcare products as well as more than 60 other high-risk categories including counterfeits, weapons, and online gambling with a multi-pronged approach that employs big data, AI-powered technology, and human expertise